Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations
Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations GlobeNewswire July 01, 2025 SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. today announced the sale of its zilovertamab and ONCT-808 programs to Ho'ola Therapeutics, Inc. Zilovertamab is an investigational monoclonal antibody designed to inhibit the function […]